Home Alzheimer’s Disease Phase III CheckMate-9ER Trial Meets Primary Endpoint in Advanced RCC Trial

Phase III CheckMate-9ER Trial Meets Primary Endpoint in Advanced RCC Trial

The pivotal phase III trial CheckMate-9ER evaluating nivolumab (Opdivo) in combination with cabozantinib (Cabometyx), compared to sunitinib (Sutent), in previously untreated advanced or metastatic renal cell carcinoma (RCC) met its primary endpoint of progression-free survival (PFS) at final analysis, according to Bristol Myers Squib and Exelixis, the developers of the agents.1

“The positive topline results from the Phase III CheckMate-9ER trial evaluating Opdivo in combination with Cabometyx build on our understanding of Opdivo-based regimens, and we look forward to working with global health authorities to help bring this new combination regimen to previously untreated patients, a population that despite recent advances, remains in need of additional therapeutic options that extend survival,” Brian Lamon, PhD, development lead of genitourinary cancers at Bristol Myers Squibb,…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

All About Glioblastoma : braincancer

A splitting headache that continues non-stop. A weak spot in the muscular tissues and being unable to stroll a small distance. Feeling abnormally sleepy at random durations of the day.For many persons with glioblastoma...

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Recent Comments